Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Prostatic Neoplasms 5Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Colonic Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Tooth, Impacted 1Testicular Neoplasms 1Smoldering Multiple Myeloma 1Oropharyngeal Neoplasms 1Neuroblastoma 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Melanoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Hepatoblastoma 1Hematologic Neoplasms 1Hemangioma, Cavernous, Central Nervous System 1Hemangioma, Cavernous 1Ganglioneuroblastoma 1Fibrolamellar hepatocellular carcinoma 1Esophageal Neoplasms 1Epstein-Barr Virus Infections 1Carcinoma, Renal Cell 1Breast Carcinoma In Situ 1Anus Neoplasms 1Anal Canal Carcinoma 1

Interventions

Lenalidomide 6carfilzomib 3Dexamethasone 3daratumumab 2Melphalan 2Leflunomide 2poly ICLC 1pembrolizumab 1isatuximab 1fludarabine phosphate 1fludarabine 1citarinostat 1Watchful Waiting 1Stem Cell Transplantation 1Peripheral Blood Stem Cell Transplantation 1PVX-410 vaccine 1Observation 1Myelography 1Metformin 1Cyclophosphamide 1Cholestyramine Resin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Smoldering Multiple Myeloma × Watchful Waiting × Clear all
NCT01169337 2026-05-01

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
226 enrolled 16 charts
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡